Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib presurgical trial for HER2-positive breast cancer brain metastases
ISRCTN38635575Phase 2Terminated
- Sponsor
- University of Liverpool
- Start
- Apr 2017
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of buparlisib in breast cancer and brain metastases, sponsored by University of Liverpool. Primary endpoint: Metabolic response by FLT-PET. Started Apr 2017; status: terminated.
02
Drugs
buparlisib
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on ISRCTN38635575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38635575.